Medtronic plc (MDT) Total Return:-5.87%(TTM)
The total return cagr for Medtronic plc (MDT) is -5.87% over the latest trailing 12-month period. The comparable SPY value is +22.12%. Year-to-date total return is -15.77%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in MDT
$93,954
(9.4x return)
Invested on Jun 10, 1996
Growth of $10,000 in SPY (S&P 500)
$181,640
(18.2x return)
Invested on Jun 10, 1996
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
-15.8%
1-Year Total Return
-5.9%
Current Dividend Yield
3.54%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | (8.8%) | (5.9%) | +2.9% |
| 3 Years | (1.4%) | +1.9% | +3.3% |
| 5 Years | (8.4%) | (5.6%) | +2.8% |
| 10 Years | (0.7%) | +2.0% | +2.6% |
| 15 Years | +5.1% | +7.7% | +2.6% |
| 20 Years | +2.3% | +4.7% | +2.4% |
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha